Very common (10% or more): Severe skin irritation (Up to 32%)
Frequency not reported: Mild irritation, peeling/skin exfoliation, erythema, pruritus, blistering, pain, crusting, tenderness, dry skin, burning/warmth/stinging, photosensitivity/increased sensitivity to light
Postmarketing reports: Temporary hyper/hypopigmentation, rash, skin atrophy
Very common (10% or more): Dry skin (Up to 16%), peeling/scaling/flaking skin (Up to 12%)
Common (1% to 10%): Burning sensation, erythema, pruritus, skin pain, sunburn
Frequency not reported: Blistering/crusting skin
Postmarketing reports: Temporary hypo/hyperpigmentation, increased susceptibility to sunlight
Common (1% to 10%): Skin irritation, skin burning, erythema, dermatitis
Frequency not reported: Peeling, dryness, stinging, itching
Postmarketing reports: Temporary hypo/hyperpigmentation [ Ref ]
Apply a thin layer to the affected area(s) once a day, at least 30 minutes before bedtime
-The affected area(s) should be washed with a mild cleanser and dried before application of this drug.
-Patients should extend application of the cream to approximately 1/2 inch of normal appearing skin (surrounding each lesion), and then the cream should rubbed lightly and uniformly into the skin.
-Treatment should be discontinued once control is achieved.
Use: Short-term treatment of moderate to severe melasma of the face, in combination with sun avoidance measures (., sunscreen use)
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: 12 Years and older (Child, Adult, Senior) Sexes Eligible for Study: All Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: